Adia Nutrition Inc. Plans Major 2026 Clinical Research Push With 4–5 New Studies, Autism Expansion, and Rheumatoid Arthritis Focus

Winter Park, Florida (February 9, 2026) — Adia Nutrition Inc. (OTCQB: ADIA), through its regenerative medicine subsidiary Adia Med, announced plans to initiate four to five new clinical studies in 2026. The company says the upcoming research will build on its existing work in regenerative therapies using Adia Vita, described by the company as an umbilical cord blood–derived stem cell and exosome-based approach.

The announcement highlights two key priority initiatives already under discussion: (1) an expansion of Adia Med’s Institutional Review Board (IRB)-approved Autism Spectrum Disorder (ASD) study to include 13-year-old children, and (2) a new dedicated study evaluating Adia Vita in people with rheumatoid arthritis (RA). Adia says these efforts are part of a broader strategy to grow its clinical pipeline, support multi-site participation, and produce higher-quality clinical data across multiple conditions.

What Adia Nutrition Inc. Announced

Adia Nutrition Inc. stated that it intends to launch four to five additional studies throughout 2026. These studies may be conducted at the Adia Med clinic in Winter Park, Florida, and/or in partnership with clinics across the United States. According to the company, Adia Med is already in discussions with multiple clinics to pursue IRB approvals that would allow multi-site clinical participation.

In plain terms, the company is trying to move from a single-site (or limited-site) research approach into a broader network. Multi-site participation can help research move faster, increase the diversity of participants, and reduce the risk that results only reflect one local patient population.

Why IRB Approval and Multi-Site Participation Matter

When a company mentions Institutional Review Board (IRB) approval, it’s pointing to an oversight process designed to protect participants and ensure studies follow ethical rules. An IRB typically reviews clinical study plans to confirm that:

• Participants are informed about what will happen and what risks may exist

• Consent procedures are appropriate for the patient population (especially important in pediatric research)

• Safety monitoring and reporting plans are in place

• Data handling respects privacy and regulatory requirements

Adia Nutrition Inc. says it is pursuing IRB approvals to enable multi-site participation in 2026. That could be meaningful for families and patients because more sites may reduce travel burdens, improve access, and increase enrollment speed—especially in conditions where families may be spread across states or even countries.

Autism Study Expansion: Adding 13-Year-Old Eligibility

One of the most specific items in the announcement is the planned expansion of Adia Med’s IRB-approved Autism Spectrum Disorder (ASD) study listed on ClinicalTrials.gov as NCT07304440. The company says it is discussing an update that would include 13-year-old children, extending eligibility beyond the current ages 3–12.

That change may sound small—just one year—but it could be important. Many families seek new options as children move into early adolescence, where developmental needs can shift and educational or social challenges may become more complex. Expanding eligibility by even a year can open the door for additional participants who otherwise would be excluded based on age alone.

What the Protocol Includes (As Described by the Company)

Adia Nutrition Inc. stated that the autism protocol combines Adia Vita with glutathione therapy. In the release, the company frames this as an “innovative protocol” intended to support research into regenerative approaches in a neurodevelopmental condition.

It’s important to note that a clinical study is designed to gather data—about feasibility, safety, and potentially signals of effectiveness—under defined rules and oversight. The company also emphasized that research is conducted under ethical oversight, informed consent, and regulatory compliance.

The Current ASD Trial Status

Adia Nutrition Inc. described its flagship human trial as a 24-month ASD study that remains actively recruiting children aged 3–12 “nationwide and worldwide.” The company said the study follows approval by BeyondBound IRB in late 2025. It also noted that conversations with partner clinics are progressing, with targeted IRB submissions expected in the coming months to support the broader 2026 agenda.

If you want to see the public listing for the study, you can search ClinicalTrials.gov for the identifier, or use this reference link: ClinicalTrials.gov — NCT07304440.

New 2026 Rheumatoid Arthritis Study: What It Could Explore

The second major item in the announcement is a planned new study in rheumatoid arthritis (RA). Adia Nutrition Inc. says this research would evaluate Adia Vita in RA patients and explore potential immune-modulating and anti-inflammatory effects in autoimmune and inflammatory conditions.

Rheumatoid arthritis is a chronic autoimmune condition where the immune system can attack joints and other tissues, often leading to pain, stiffness, swelling, and fatigue. Many people manage RA with long-term treatment plans that can include medications, therapy, lifestyle changes, and careful monitoring. Because RA is complex, research into new approaches typically focuses on safety, inflammation markers, functional outcomes, symptom tracking, and quality-of-life measures.

Why a Dedicated RA Study Is a Notable Step

Adia Nutrition Inc. is signaling a broadening of its research scope from neurodevelopmental studies into autoimmune and inflammatory conditions. A dedicated RA study could provide structured data on:

• Participant selection (who may benefit and who may not)

• Safety and tolerability for an autoimmune population

• Inflammation-related outcomes tracked over time

• Function and symptom changes using standardized tools

Even if a study begins small, it can help define the right endpoints and study design for future, larger research. That’s often how clinical pipelines develop: early studies create the foundation for stronger, more targeted trials later.

Where the 2026 Studies May Take Place

Adia Nutrition Inc. stated that planned studies may be conducted directly at the Adia Med clinic in Winter Park, Florida or through collaborations with partner clinics across the United States. This hybrid model—one main site plus partner sites—can allow a company to keep a consistent standard while also reaching more participants.

To make that work, a network typically needs clear protocols, staff training, consistent data collection methods, and aligned patient follow-up schedules. That is one reason companies often emphasize IRB coordination and regulatory compliance when describing multi-site plans.

Company Leadership Comments

In the announcement, CEO Larry Powalisz said launching four to five new studies in 2026 is a major step in the company’s commitment to rigorous, ethical clinical research. He also said that working with clinics nationwide could accelerate IRB approvals, broaden patient access, and generate higher-quality data across neurodevelopmental, autoimmune, and other regenerative applications.

This leadership messaging matters in a public-company context because it sets expectations for investors, clinics, and patients. It also frames how the company wants the market to understand its strategy: not just offering services, but creating a research-driven pipeline intended to generate formal study outcomes.

What Adia Vita Is (In the Company’s Words)

Adia Nutrition Inc. describes Adia Vita as involving umbilical cord blood–derived stem cells and exosomes. The company positions this as the cornerstone of its regenerative therapy approach and notes that Adia Vita continues to be available for physician-directed applications in regenerative and immune-supportive contexts.

In regenerative medicine discussions, terms like “stem cells” and “exosomes” often generate strong interest. That’s why structured clinical research is important: carefully designed studies can help clarify where a therapy may be helpful, how it should be used, and what safety considerations must be monitored.

How Adia Med Describes Its Clinical and Service Focus

According to the company, Adia Med clinics focus on orthopedic care, pain management, and wound repair. The release also states that Adia Med clinics offer regenerative treatments such as stem cell therapies and platelet-rich plasma (PRP), as well as advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), plus wound repair services.

From a business perspective, Adia Nutrition Inc. says revenue is generated through service fees, product sales, equity stakes, and insurance billing for healthcare treatments. The company also notes that it invests in aligned businesses, including Cement Factory LLC, described as a nutrition and supplement company.

What This Could Mean for Patients and Families

When a company expands a clinical pipeline, the biggest real-world question is often: “Will this create more access and better evidence?” Adia Nutrition Inc.’s plan to launch four to five additional studies—and to expand to multi-site participation—could have several practical implications:

• More study slots if new trials open in multiple locations

• Less travel if partner clinics join and offer participation closer to home

• More structured follow-up through defined study timelines and measurement tools

• Clearer evidence if data collection is consistent across sites

At the same time, clinical research is not the same as guaranteed outcomes. Studies are built to find answers, and those answers can be positive, negative, or mixed. That’s why ethical oversight, careful reporting, and transparent study listings matter.

What Clinics and Practitioners Should Know

Adia Nutrition Inc. also used the announcement to invite clinic owners and healthcare practitioners to explore licensing the Adia Med name or integrating Adia’s regenerative therapies into their practices. The company stated that strategic partnerships are welcome as part of its mission to expand access to advanced stem cell solutions.

For clinics, partnerships typically raise practical questions such as:

• Training and protocol standardization across sites

• IRB coordination and documentation requirements

• Patient screening and eligibility consistency

• Data reporting expectations and privacy handling

In multi-site research, strong coordination is the difference between clean, usable data and confusing, inconsistent outcomes. The company’s emphasis on IRB approvals suggests it’s trying to lay groundwork for that kind of coordination.

Safe Harbor and Forward-Looking Statements: Why It’s Included

The press release includes a Safe Harbor section noting that the statement contains forward-looking information and that actual results may differ due to risks and uncertainties. This is common for publicly traded companies, especially when discussing plans and expectations for future studies, partnerships, or growth.

In other words, the company is sharing what it intends to do in 2026, but it is also reminding readers that timelines can shift due to approvals, logistics, enrollment speed, regulatory decisions, and other factors.

Frequently Asked Questions (FAQs)

1) How many new clinical studies does Adia Nutrition Inc. plan to start in 2026?

Adia Nutrition Inc. said it plans to initiate four to five new clinical studies throughout 2026, building on its current clinical research pipeline.

2) What is changing in the autism study?

The company says it is discussing an expansion of its IRB-approved ASD study (ClinicalTrials.gov NCT07304440) to include 13-year-old children, extending eligibility beyond the current 3–12 age range.

3) What new condition is Adia planning to study in 2026?

Adia Nutrition Inc. stated it intends to launch a new rheumatoid arthritis (RA) study to evaluate Adia Vita in RA patients and explore potential immune-modulating and anti-inflammatory effects.

4) Where will these studies take place?

The company said studies may be conducted at the Adia Med clinic in Winter Park, Florida, and/or with partner clinics across the United States, depending on IRB approvals and collaboration arrangements.

5) What does IRB approval mean in this context?

IRB approval refers to review by an Institutional Review Board, an independent body that evaluates whether a study is ethically designed, includes appropriate informed consent, and protects participant rights and safety.

6) Is the autism study currently recruiting participants?

Yes. Adia Nutrition Inc. described the 24-month ASD study as actively recruiting children aged 3–12, with the study following BeyondBound IRB approval in late 2025.

Conclusion: A Big 2026 Research Roadmap With Clear Priorities

Adia Nutrition Inc.’s February 9, 2026 announcement outlines a substantial 2026 plan: four to five new studies, expanded multi-site efforts, and two standout priorities—expanding ASD eligibility to include 13-year-olds and launching a new rheumatoid arthritis study. If the company successfully secures IRB approvals and partner participation, 2026 could become a defining year for the pace and scale of its clinical research program.

For patients and families, the most meaningful outcomes will be whether research expands access, strengthens oversight, and produces clear, usable data. For clinics, the key question will be how well protocols and participation are standardized across sites. And for the market, the focus will remain on whether the company can convert ambitious plans into well-executed studies and transparent results.

Reference: The original company release was published via Newsfile on February 9, 2026.

#AdiaNutrition #AdiaMed #ClinicalTrials #RegenerativeMedicine #SlimScan #GrowthStocks #CANSLIM